
Tempus AI Buys Personalis for $1.5 Billion
A massive consolidation in cancer diagnostics reveals the steep financial price of dominating the liquid biopsy market.
Discover the newest research about AI innovations in π Oncology.

A massive consolidation in cancer diagnostics reveals the steep financial price of dominating the liquid biopsy market.

A new multimodal AI model helps solve the agonizing clinical dilemma of whether breast cancer survivors should endure five extra years of hormone therapy.

A new study shows AI-generated synthetic patients can replicate cancer trial results, potentially shrinking the need for human control groups.

Averaging tumor data has long blinded oncologists to the specific, high-risk cells that drive patient mortality.

A new machine learning model uses simple blood and nutrition markers to predict which uterine cancer patients can safely skip aggressive surgery to preserve their fertility.

A new AI model turns the standard complete blood count into an instant classifier for leukemia and severe infections, bypassing the slow manual slide review that delays critical care.

Doubling scanning capacity is useless if there are no radiologists left to read the scans.

A new AI-driven blood test could soon keep thousands of women out of the imaging room by ruling out womb cancer with near-perfect accuracy.

A new regulatory shortcut could quietly solve the worst bottleneck in cancer treatment.

When algorithms read pathology reports better than the oncologists who ordered them, the bottleneck in cancer care shifts from diagnostic accuracy to human administrative capacity.